Redeye: Xvivo Perfusion - Please hold

The third quarter of the year showed weaker-than-expected sales growth for Xvivo Perfusion, failing to live up to our high set expectations. We revise our estimates with lower sales growth in the near-term, but with reimbursement codes for the EVLP procedure in hand and progression in the research portfolio, our view of the company’s long-term potential remains intact. 

Access the Research Update by Arvid Necander at:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.